- Home
- MDCX vs SNTI Comparison
MDCX vs SNTI Comparison
Compare MDCX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | SNTI |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 22.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDCX | SNTI |
|---|---|---|
| Price | $1.54 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.50 | $9.00 |
| AVG Volume (30 Days) | ★ 456.7K | 151.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.80 |
| 52 Week High | $8.90 | $5.10 |
Technical Indicators
Market Signals| Indicator | MDCX | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 46.93 |
| Support Level | $1.45 | $0.80 |
| Resistance Level | $1.70 | $1.19 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 71.91 | 61.81 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.